Attached files

file filename
EX-99.2 - PRESS RELEASE - Ohr Pharmaceutical Incex-99_2.htm
EX-99.1 - ARVO POSTER PRESENTATION - Ohr Pharmaceutical Incex-99_1.htm





Washington, D.C. 20549


Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2012

Ohr Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)

Delaware   333-88480   #90-0577933
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)


489 5th Ave, 28th Floor, New York, NY   10017
(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: (212)-682-8452


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


ITEM 7.01. Regulation FD Disclosure.


On May 6, 2012, Ohr Pharmaceutical Inc. (the "Company") presented a poster presentation discussing biodistribution and safety data on the Squalamine eye drop. The poster is attached to this Current Report on Form 8-K as exhibit 99.1 and will be available on the investor page of the company’s website.

The information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, "Regulation FD Disclosure." This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01.  Other Items.


On May 7, 2012, the Company issued a press release announcing the safety and biodistribution results of a preclinical study for the Squalamine eye drop program presented at ARVO on May 6, 2012.


A copy of the press release is attached to this Current Report on Form 8-K as exhibit 99.2.


ExhibitNo. Description

99.1ARVO Poster Presentation dated May 6, 2012
99.2Squalamine Study Results Press Release dated May 7, 2012




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 Dated: May 9, 2012
    By: /s/ Irach Taraporewala
    Name: Dr. Irach Taraporewala
    Title: President and CEO